Vanda Pharmaceuticals Breaks 40 Year Motion Sickness Drug Drought With FDA Approval

Vanda Pharma achieved a historic milestone with FDA approval of NEREUS (tradipitant) for motion sickness prevention, the first new treatment in 40 years.

Zoliflodacin Breakthrough: Single-Dose Pill Tackles Antibiotic-Resistant Gonorrhea

A groundbreaking phase 3 clinical trial published in The Lancet has demonstrated that zoliflodacin, a single-dose oral antibiotic, matches the effectiveness of current standard treatments for gonorrhea while offering significant advantages in simplicity and accessibility. This development represents a critical breakthrough in the ongoing battle against antibiotic-resistant sexually transmitted infections,

Neuralink's Production Scale-Up Marks Neurotechnology's Commercial Turning Point

Neuralink's announcement to scale up brain-computer interface production in 2026 signals a potential inflection point for the neurotechnology sector, with implications for accessibility and cost reduction.